Prospective randomized control study of efficacy of transcatheter arterial chemoembolization (TACE) with Miriplatin vs. Epirubicin for recurrent hepatocellular carcinoma after TACE

INTERVENTION: Miriplatin TACE Epirubicin TACE CONDITION: hepatocellular carcinoma PRIMARY OUTCOME: Tumor response SECONDARY OUTCOME: Overall survival, progression free survival, time to treatment failure, tumor marker change, safety INCLUSION CRITERIA: 1) Histologically proven or clinically diagnosed hepatocellular carcinoma. Number of tumors are up to 10. 2) Patients who have a recurrence after Epirubicin TACE. 3) Patients who fulfill of the inclusion criteria below. 1. PLT >=30000/mm3 2. T.Bil <=3.0mg/dl 3. Cr <=1.5mg/dl 4) Performance status (ECOG) of 0‐2 5) The patient without anamunesis of the hypersensitivity to drug utilization 6) Without tumor thrombosis in main portal branch or portal trunk 7) Child‐Pugh class A or B. 8) Without pregnant, lactating women or women with suspected pregnancy 9) Patients who were provided written informed consent